Prim-O-glucosylcimifugin ameliorates DSS-induced ulcerative colitis via suppressing NLRP3 inflammasome activation
Frontiers in Pharmacology · 19.03.2026 · 17
DOI: 10.3389/fphar.2026.1750305 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 19.03.2026. Verfasst von Fuqian Wang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Wuhan No.1 Hospital, Wuhan, China. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Ulcerative colitis (UC) is a chronic and relapsing inflammatory bowel disease (IBD), that lacks specific therapeutic drugs. Prim-O-glucosylcimifugin (POG), a furanochromone glycoside derived from Saposhnikovia divaricata , exhibits anti-inflammatory, antioxidant, and anti-inflammasome activities. It has also been shown to inhibit the activation of the NLR family pyrin domain containing 3 (NLRP3) inflammasome. Given that ulcerative colitis (UC) is a chronic inflammatory bowel disease characterized by intestinal barrier dysfunction and NLRP3 activation, this study aims to investigate the therapeutic effects and underlying mechanisms of POG in a murine model of UC induced by dextran sulfate sodium (DSS), and to evaluate its potential translational significance for UC intervention.
Methods
A DSS-induced UC mouse model was employed to evaluate POG’s therapeutic efficacy. Disease activity index, colon length, spleen index, and histopathological alterations of the colonic mucosa were assessed by H&E and AB-PAS staining, transmission electron microscopy, and immunofluorescence. Proinflammatory cytokines (TNF-α, IL-6, IL-18, IL-1β) were measured by ELISA, and NLRP3 inflammasome–related proteins were analyzed by Western blot.
Results
POG treatment alleviated weight loss, colon shortening, splenomegaly, and inflammatory infiltration. It also restored goblet cell mucin droplets and tight junction proteins (Occludin, ZO-1, Claudin-1, MUC2), and reduced villi exfoliation. Serum levels of TNF-α, IL-6, IL-1β, and IL-18 were decreased. Western blot and ELISA revealed that POG suppressed NLRP3 inflammasome formation, inhibited GSDMD activation, and reduced cleavage and release of IL-1β and IL-18. Collectively, these findings indicate that POG not only attenuates inflammatory injury but also protects epithelial barrier structure and function, supporting its potential value in mechanism-based UC therapy development.
Conclusion
POG ameliorates experimental UC by inhibiting NLRP3 inflammasome activation, thereby mitigating colonic inflammation, preserving mucosal barrier integrity, and blocking downstream inflammatory responses. POG shows promise as a therapeutic agent for UC and provides a rationale for further preclinical optimization and future clinical translation.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmacy, Wuhan No.1 Hospital, Wuhan, China.
- School of Foreign Languages, Hubei University of Chinese Medicine, Wuhan, China.
- Department of Pharmacy, Traditional Chinese and Western Medicine Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Zitieren
APA
Wang, F., Xiong, X., Ruan, Q., Zhang, D., Huang, C., Xie, T., & Cheng, L. (2026). Prim-O-glucosylcimifugin ameliorates DSS-induced ulcerative colitis via suppressing NLRP3 inflammasome activation. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.1750305
Vancouver
Wang F, Xiong X, Ruan Q, Zhang D, Huang C, Xie T, et al. Prim-O-glucosylcimifugin ameliorates DSS-induced ulcerative colitis via suppressing NLRP3 inflammasome activation. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.1750305
BibTeX
@article{Wang2026,
author = {Wang, Fuqian and Xiong, Xin and Ruan, Qingfeng and Zhang, Dan and Huang, Chuanqi and Xie, Tingting and Cheng, Lu},
title = {Prim-O-glucosylcimifugin ameliorates DSS-induced ulcerative colitis via suppressing NLRP3 inflammasome activation},
journal = {Frontiers in Pharmacology},
year = {2026},
volume = {17},
doi = {10.3389/fphar.2026.1750305}
}
EUVIMED